• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Venus Concept Shares Are Trading Higher By Over 63%? Here Are 58 Stocks Moving In Wednesday's Mid-Day Session

    12/21/22 1:51:35 PM ET
    $ADPT
    $AKTX
    $ALT
    $ATNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADPT alert in real time by email

    Gainers

    • Sintx Technologies, Inc. (NASDAQ:SINT) shares climbed 81.4% to $13.55 after the company was awarded Phase I contract for $150,000 from the Missile Defense Agency for electrochemical machining.
    • Venus Concept Inc. (NASDAQ:VERO) gained 63.3% to $0.4122 after the company announced it received a 510(k) clearance from the FDAto market its AI.ME next generation robotic technology for fractional skin resurfacing.
    • Laser Photonics Corporation (NASDAQ:LASE) jumped 40% to $2.1499 after the company announced it received an order from the largest glass manufacturer in North America.
    • Cenntro Electric Group Limited (NASDAQ:CENN) rose 33.6% to $0.3561. Cenntro started shipments of LS260 and LS100 vans to European Markets.
    • F-star Therapeutics, Inc. (NASDAQ:FSTX) gained 29.9% to $5.59.
    • Rekor Systems, Inc. (NASDAQ:REKR) jumped 28% to $0.7622. Rekor announced financing to solidify cash position and accelerate business growth and technology development.
    • Mobile Global Esports Inc. (NASDAQ:MGAM) jumped 25% to $0.7885. Maxim Group initiated coverage on Mobile Global Esports with a Buy rating and announced a price target of $1.5.
    • Kineta, Inc. (NASDAQ:KA) surged 25% to $4.70.
    • Blue Star Foods Corp. (NASDAQ:BSFC) gained 23.7% to $0.5319.
    • Appreciate Holdings, Inc. (NASDAQ:SFR) rose 22.6% to $1.68.
    • BeyondSpring Inc. (NASDAQ:BYSI) gained 22.5% to $2.07.
    • Erayak Power Solution Group Inc. (NASDAQ:RAYA) gained 22.1% to $3.2955 after jumping over 47% on Tuesday.
    • Ecoark Holdings, Inc. (NASDAQ:ZEST) rose 21.4% to $0.34.
    • Grove Collaborative Holdings, Inc. (NYSE:GROV) rose 21% to $0.2476. Grove announced receipt of continued listing standards notice from NYSE.
    • Akari Therapeutics, Plc (NASDAQ:AKTX) gained 20.6% to $0.5347.
    • CalAmp Corp. (NASDAQ:CAMP) gained 20.1% to $4.12 after the company reported better-than-expected Q3 sales results.
    • DatChat, Inc. (NASDAQ:DATS) surged 19.4% to $0.4211.
    • Zymeworks Inc. (NASDAQ:ZYME) rose 18.6% to $8.40. Jazz Pharmaceuticals and Zymeworks announced that Jazz has exercised option to continue exclusive development and commercialization rights to Zanidatamab.
    • Evelo Biosciences, Inc. (NASDAQ:EVLO) jumped 18.5% to $1.73.
    • Pagaya Technologies Ltd. (NASDAQ:PGY) gained 18.4% to $0.7862.
    • Altimmune, Inc. (NASDAQ:ALT) gained 18.2% to $14.07. Altimmune announced topline results from its 24-week (12-week extension) trial of pemvidutide in subjects with Non-Alcoholic Fatty Liver Disease (NAFLD).
    • Forian Inc. (NASDAQ:FORA) climbed 18.1% to $2.5750. New York has selected Forian's Biotrack as the State's Cannabis Seed to sale track and trace system.
    • Adaptive Biotechnologies Corporation (NASDAQ:ADPT) gained 17.7% to $8.35 after Piper Sandler upgraded the stock from Neutral to Overweight and raised its price target from $7.5 to $14.
    • Mereo BioPharma Group plc (NASDAQ:MREO) surged 16.2% to $0.6160.
    • Avaya Holdings Corp. (NYSE:AVYA) gained 14.6% to $0.2386.
    • NIKE, Inc. (NYSE:NKE) rose 13.9% to $117.51 after the company reported better-than-expected results for its second quarter on Tuesday.
    • TransCode Therapeutics, Inc. (NASDAQ:RNAZ) rose 13.2% to $0.3751 after dropping 27% on Tuesday.
    • Nine Energy Service, Inc. (NYSE:NINE) gained 12.7% to $11.89.
    • Six Flags Entertainment Corporation (NYSE:SIX) surged 12.3% to $23.50 after Land & Buildings issued a presentation highlighting an opportunity to unlock substantial real estate value at Six Flags. Land & Buildings is approximately a 3% shareholder of Six Flags.
    • Butterfly Network, Inc. (NYSE:BFLY) shares gained 11.1% to $2.4550. Butterfly Network recently completed successful deployment of 500 Butterfly iQ+ devices and training of 500+ healthcare workers across 224 facilities in Kenya.
    • 374Water, Inc. (NASDAQ:SCWO) jumped 10.8% to $2.77.
    • Energy Focus, Inc. (NASDAQ:EFOI) rose 7.6% to $0.3434 after declining 11% on Tuesday. Energy Focus, last month, posted a Q3 loss of $0.29 per share.
    • FedEx Corporation (NYSE:FDX) rose 4% to $170.79. FedEx posted upbeat earnings for its second quarter, while sales missed expectations. The company also said it sees FY23 earnings of $13.00 to $14.00 per share, versus analysts’ estimates of $14.08 per share.

     


    Losers

    • Pingtan Marine Enterprise Ltd. (NASDAQ:PME) shares fell 100% to $0.0001.
    • Meiwu Technology Company Limited (NASDAQ:WNW) dropped 78% to $0.4099.
    • Core Scientific, Inc. (NASDAQ:CORZ) shares dipped 50.5% to $0.1026 after the company filed for Chapter 11 bankruptcy.
    • IceCure Medical Ltd (NASDAQ:ICCM) fell 39.8% to $1.5650. IceCure reported pricing of 8,787,880 share public offering at $1.65 per share.
    • Celyad Oncology SA (NASDAQ:CYAD) fell 37.4% to $0.6516 after the company reported it has decided to discontinue the development of its remaining clinical program CYAD-211.
    • WeTrade Group, Inc. (NASDAQ:WETG) declined 25.7% to $0.2860.
    • Singularity Future Technology Ltd. (NASDAQ:SGLY) dropped 23.6% to $0.5599.
    • Vivos Therapeutics, Inc. (NASDAQ:VVOS) fell 20.7% to $0.42 after posting a loss for the third quarter.
    • Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) fell 20.6% to $3.7399.
    • UTime Limited (NASDAQ:UTME) fell 20% to $0.9998.
    • Ostin Technology Group Co., Ltd. (NASDAQ:OST) dropped 18.9% to $0.7773.
    • Quotient Limited (NASDAQ:QTNT) fell 17.8% to $0.2334.
    • Athenex, Inc. (NASDAQ:ATNX) fell 17% to $0.1327. Athenex announced Quantum Leap Healthcare Collaborative reported a trial result of I-SPY2 trial for oral paclitaxel in combination with PD-1 and carboplatin in neoadjuvant breast cancer.
    • Magenta Therapeutics, Inc. (NASDAQ:MGTA) dipped 15.9% to $0.33. BTIG maintained Magenta Therapeutics with a Buy and lowered the price target from $6 to $3.
    • Caravelle International Group (NASDAQ:CACO) dropped 15.2% to $1.79 after dropping 57% on Tuesday.
    • Rite Aid Corporation (NYSE:RAD) shares fell 13.9% to $11.89 after the company reported results for its third quarter.
    • Lion Group Holding Ltd. (NASDAQ:LGHL) fell 13.5% to $1.2450.
    • Surrozen, Inc. (NASDAQ:SRZN) dropped 13.4% to $0.43.
    • GEE Group, Inc. (NYSE:JOB) fell 12.6% to $0.5661 after the company reported worse-than-expected Q4 sales results.
    • Calavo Growers, Inc. (NASDAQ:CVGW) dropped 11.6% to $29.92 after the company reported worse-than-expected Q4 EPS and sales results.
    • BlackBerry Limited (NYSE:BB) fell 7.8% to $3.82 after the company reported Q4 earnings results.
    • Lanvin Group Holdings Limited (NYSE:LANV) dropped 7.8% to $6.76.
    • Cosmos Health Inc. (NASDAQ:COSM) fell 7.1% to $8.14 after gaining 15% on Tuesday. Cosmos Health recently announced pricing of a $32.5 million registered direct offering and concurrent private placement priced at-the-market.
    • Terns Pharmaceuticals, Inc. (NASDAQ:TERN) fell 6.6% to $7.89 after the company reported pricing of $75 million public offering.
    • Pebblebrook Hotel Trust (NYSE:PEB) fell 5.2% to $13.66 after the company lowered its FY22 FFO per share guidance.

    Read This Next: Bitcoin Edges Higher But Remains Below This Key Level; Helium Emerges As Top Gainer

    Get the next $ADPT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADPT
    $AKTX
    $ALT
    $ATNX

    CompanyDatePrice TargetRatingAnalyst
    Altimmune Inc.
    $ALT
    4/24/2026$2.50Sell → Neutral
    Goldman
    Surrozen Inc.
    $SRZN
    4/21/2026Buy
    TD Cowen
    CAMP4 Therapeutics Corporation
    $CAMP
    4/14/2026$7.00Buy
    Rodman & Renshaw
    SiNtx Technologies Inc.
    $SINT
    4/13/2026$10.00Buy
    H.C. Wainwright
    Nike Inc.
    $NKE
    4/13/2026$48.00Buy → Hold
    HSBC Securities
    Nike Inc.
    $NKE
    4/10/2026$50.00Overweight → Neutral
    Piper Sandler
    Akari Therapeutics plc
    $AKTX
    4/8/2026Buy → Hold
    Maxim Group
    Nike Inc.
    $NKE
    4/1/2026$52.00Overweight → Neutral
    Analyst
    More analyst ratings

    $ADPT
    $AKTX
    $ALT
    $ATNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tcg Crossover Gp Ii, Llc bought $1,220,362 worth of shares (48,997 units at $24.91) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    3/16/26 7:05:51 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Weiss Eric Stanton bought $101,700 worth of shares (7,000 units at $14.53), increasing direct ownership by 3% to 252,262 units (SEC Form 4)

    4 - Core Scientific, Inc./tx (0001839341) (Issuer)

    3/10/26 4:08:53 PM ET
    $CORZ
    Finance: Consumer Services
    Finance

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $ADPT
    $AKTX
    $ALT
    $ATNX
    SEC Filings

    View All

    SEC Form DEFA14A filed by Adaptive Biotechnologies Corporation

    DEFA14A - Adaptive Biotechnologies Corp (0001478320) (Filer)

    4/24/26 4:31:02 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEF 14A filed by Adaptive Biotechnologies Corporation

    DEF 14A - Adaptive Biotechnologies Corp (0001478320) (Filer)

    4/24/26 4:30:23 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form S-3/A filed by Cosmos Health Inc.

    S-3/A - Cosmos Health Inc. (0001474167) (Filer)

    4/24/26 4:30:45 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $ADPT
    $AKTX
    $ALT
    $ATNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Altimmune upgraded by Goldman with a new price target

    Goldman upgraded Altimmune from Sell to Neutral and set a new price target of $2.50

    4/24/26 7:59:47 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Surrozen

    TD Cowen initiated coverage of Surrozen with a rating of Buy

    4/21/26 7:35:41 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rodman & Renshaw initiated coverage on CAMP4 Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of CAMP4 Therapeutics with a rating of Buy and set a new price target of $7.00

    4/14/26 8:19:24 AM ET
    $CAMP

    $ADPT
    $AKTX
    $ALT
    $ATNX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for FAMOTIDINE issued to ATHENEX INC

    Submission status for ATHENEX INC's drug FAMOTIDINE (SUPPL-13) with active ingredient FAMOTIDINE has changed to 'Approval' on 01/07/2022. Application Category: ANDA, Application Number: 075684, Application Classification: Labeling

    1/12/22 4:41:30 AM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    March 5, 2021 - Coronavirus (COVID-19) Update: FDA Authorizes Adaptive Biotechnologies T-Detect COVID Test

    For Immediate Release: March 05, 2021 Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the T-Detect COVID Test developed by Adaptive Biotechnologies. The T-Detect COVID Test is a next generation sequencing based (NGS) test to aid in identifying individuals with an adaptive T cell immune response to SARS-CoV-2, indicating recent or prior infection with SARS-CoV-2.  “Today’s authorization further und

    3/5/21 10:37:33 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for KLISYRI

    Submission status for ATHENEX INC's drug KLISYRI (ORIG-1) with active ingredient TIRBANIBULIN has changed to 'Approval' on 12/14/2020. Application Category: NDA, Application Number: 213189, Application Classification: Type 1 - New Molecular Entity

    12/20/20 4:30:55 PM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADPT
    $AKTX
    $ALT
    $ATNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and COO Rubinstein Julie exercised 44,166 shares at a strike of $8.46 and sold $798,423 worth of shares (57,180 units at $13.96) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 382,132 units (SEC Form 4)

    4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)

    4/24/26 6:29:47 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form 4 filed by Hill Elliott

    4/A - NIKE, Inc. (0000320187) (Issuer)

    4/22/26 4:57:24 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    SEC Form 4 filed by Subramaniam Rajesh

    4 - FEDEX CORP (0001048911) (Issuer)

    4/22/26 4:53:53 PM ET
    $FDX
    Air Freight/Delivery Services
    Consumer Discretionary

    $ADPT
    $AKTX
    $ALT
    $ATNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Core Scientific, Inc. Schedules First Quarter Fiscal Year 2026 Earnings Release, Conference Call and Webcast

    Core Scientific, Inc. (NASDAQ:CORZ) ("Core Scientific" or the "Company"), a leader in digital infrastructure for high-density colocation ("HDC"), today announced it will release its first quarter 2026 financial results after the financial markets close on Wednesday, May 6, 2026. Management will host a conference call and live audio webcast to discuss the results at 3:30 p.m. Central Time. Hosting the call and webcast to review results for the first quarter 2026 will be Adam Sullivan, Chief Executive Officer, Matt Brown, Chief Operating Officer, Jim Nygaard, Chief Financial Officer, and Jon Charbonneau, Vice President, Investor Relations. Conference Call and Webcast Event Summary Date:

    4/24/26 4:30:00 PM ET
    $CORZ
    Finance: Consumer Services
    Finance

    Pagaya Closes $500 Million AAA-Rated Auto ABS Transaction; Demonstrating Continued Investor Confidence

    RPM-2026-2 is the largest Auto ABS deal in Pagaya's history More than $3.5 billion of capital raised year-to-date to fund all asset classes in Pagaya's ABS program Pagaya Technologies LTD. (NASDAQ:PGY) ("Pagaya" or the "Company"), a global technology company delivering AI-driven product solutions for the financial ecosystem, today announced the closing of RPM-2026-2, a $500 million auto asset-backed securitization (ABS). Pagaya's RPM shelf, now in its seventh year, continues to be a trusted source of high-quality collateral serviced by the country's top auto lenders. "The successful execution of RPM-2026-2 is a testament to the trust we've built within the investment community over

    4/24/26 8:30:00 AM ET
    $PGY
    Finance: Consumer Services
    Finance

    Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with Merck's pending acquisition of Terns Pharmaceuticals, Inc. ("Terns") (NASDAQ:TERN) expired at 11:59 p.m., Eastern Time, on April 23, 2026. As previously announced on April 7, 2026, Merck commenced, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Terns, for $53.00 net in cash for each share of Terns common stock validly tendered and not validly withdrawn in the offer, without interest and less any applicable tax withholding. The ex

    4/24/26 6:45:00 AM ET
    $MRK
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADPT
    $AKTX
    $ALT
    $ATNX
    Leadership Updates

    Live Leadership Updates

    View All

    Butterfly Network Appoints Arun Nagdev, MD as Chief Medical Officer – POCUS

    Prominent POCUS thought leader joins to advance clinical strategy and further Butterfly's mission to democratize ultrasound worldwide. Butterfly Network (NYSE:BFLY), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the appointment of Arun Nagdev, MD as Chief Medical Officer – Point-of-Care Ultrasound (POCUS). In this role, Dr. Nagdev will lead the global medical strategy for the Company's core POCUS business, advancing clinical product validation, strengthening customer engagement, and supporting regulatory and clinical development efforts. Dr. Nagdev brings more than 20 years of experience advancing POCUS adoption, educ

    4/21/26 8:05:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

    • Adam Schayowitz, Ph.D., MBA appointed as Head of R&D• Scott Platshon appointed as Chief Business Officer  VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the full-time appointments of Dr. Adam Schayowitz and Mr. Scott Platshon as of April 9, 2026, from their previously interim roles. Both Dr. Schayowitz and Mr. Platshon will report directly to Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. "These appointments come at a pivotal time for Zymeworks as we e

    4/9/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Appoints Kristin Stafford as Chief Financial Officer

    VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the appointment of Ms. Kristin Stafford as Chief Financial Officer, effective April 1, 2026. "Kristin brings deep experience across the life sciences industry, with a strong track record in strategic planning, disciplined capital allocation, and executing complex capital markets and strategic transactions, including acquisitions, during her time at Royalty Pharma," said Kenneth Galbraith, Chair and Chief Executive Officer. "We a

    4/1/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADPT
    $AKTX
    $ALT
    $ATNX
    Financials

    Live finance-specific insights

    View All

    Core Scientific, Inc. Schedules First Quarter Fiscal Year 2026 Earnings Release, Conference Call and Webcast

    Core Scientific, Inc. (NASDAQ:CORZ) ("Core Scientific" or the "Company"), a leader in digital infrastructure for high-density colocation ("HDC"), today announced it will release its first quarter 2026 financial results after the financial markets close on Wednesday, May 6, 2026. Management will host a conference call and live audio webcast to discuss the results at 3:30 p.m. Central Time. Hosting the call and webcast to review results for the first quarter 2026 will be Adam Sullivan, Chief Executive Officer, Matt Brown, Chief Operating Officer, Jim Nygaard, Chief Financial Officer, and Jon Charbonneau, Vice President, Investor Relations. Conference Call and Webcast Event Summary Date:

    4/24/26 4:30:00 PM ET
    $CORZ
    Finance: Consumer Services
    Finance

    Grove to Report First Quarter 2026 Financial Results on May 7, 2026

    Grove Collaborative Holdings, Inc. (NYSE:GROV) ("Grove" or "the Company"), the world's first plastic-neutral retailer and a leading sustainable consumer products company, Certified B Corporation, and Public Benefit Corporation today announced that it will report first quarter 2026 financial results after the market closes on Thursday, May 7, 2026. The Company will host an investor conference call and webcast to review these financial results at 5:00pm ET / 2:00pm PT on the same day. The webcast can be accessed at https://investors.grove.co/. The conference call can be accessed by calling 877-413-7205. International callers may dial +1 201-689-8537. A replay of the call will be available u

    4/23/26 4:05:00 PM ET
    $GROV
    Catalog/Specialty Distribution
    Consumer Discretionary

    IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025

    The Company's participation at the Society of Breast Imaging Symposium and other upcoming medical conferences are timely as commercial momentum acceleratesCryoablation cost analysis study from Massachusetts General Hospital featuring ProSense® demonstrated 50% reduction in cost vs. lumpectomy won SBI 2026 Abstract AwardCAESAREA, Israel, April 21, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it expects to report U.S. revenue of ProSense® systems and cryoprobes increased more than 30% in

    4/21/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    $ADPT
    $AKTX
    $ALT
    $ATNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Akari Therapeutics plc

    SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)

    12/6/24 4:00:28 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    11/15/24 10:35:07 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by BeyondSpring Inc.

    SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)

    11/14/24 9:52:50 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care